Magnetic resonance imaging

“Sick” MRI syndrome

M J Kushner

At this time, MRI is a better indicator of tissue outcome rather than clinical destiny

The report by Marx et al (this issue, pp572–575) joins the ever growing literature dealing with multiparametric MRI studies of tissue characteristics in stroke. Markers of ischaemic perturbations of cell homeostasis and perfusion, including changes in diffusion and perfusion weighted imaging (DWI and PWI), seem now to allow human stroke studies more analogous to animal models. Although debate rages, current optimism maintains that MRI delineates the three main tissue compartments in ischaemia. Conceptually these compartments are (a) irreversibly damaged tissue, (b) minimally disrupted tissue destined for eventual recovery, and (c) the “penumbra” or “borderzone” or “at-risk” region where outcome hangs in the balance between irrecoverable damage and some degree of recovery, and which may be amenable to treatment.1

Recent human data suggest that DWI and DWI-PWI mismatches strongly predict tissue outcome after ischaemia.2 Despite this progress in neuroimaging, clinical and clinicopathological MRI correlation has lagged behind. Reconciling recent MRI studies of stroke with each other is not straightforward, and it is also daunting to relate them to previous investigations of stroke using other reliable structural and haemometabolic techniques.31 To date, human MRI studies have used many different paradigms, and this situation stands in contrast with standardised models found in the animal stroke literature. Variations in clinical criteria, imaging protocols, and myriad other factors introduce obvious confounding influences in these studies, and it should be assumed that lack of standardised approaches can only increase exposure to not so obvious bias.

Marx et al report a relatively high incidence of DWI changes following posterior circulation ischaemia where the clinical syndrome actually was transient or reversible. DWI alterations tended to be more prominent with longer lasting ischaemic symptoms yet were detected despite ultimate clinical recovery. This bears mention, indeed, for one would expect the observed DWI changes to bode ill when in actuality full recovery was the case. This represents a potential quandary: how should one reconcile a “sick” MRI with a healthy patient? A simple explanation may be that, at this time, MRI is a better indicator of tissue outcome rather than clinical destiny. If future reports invoke MRI as an indicator of clinical outcome, or as a marker of the impact of therapeutic intervention, then data will be needed across the full spectrum of stroke severity from fixed deficits to transient syndromes. Standardised study designs are needed so that the true utility of functional MRI is established in both natural history and interventional studies of stroke. Consensus on this score would be useful now, for the widespread availability of MRI, in contrast with other techniques such as PET or SPECT, suggests that this literature will continue to proliferate.

While this field remains in flux, clinical neurology should take note. At a minimum, these MRI markers of ischaemia must be regarded as new harbingers in the menagerie threatening haemometabolic risk, and attention must be paid. Their appearance should spur the clinician to redouble efforts to apply available medical and surgical treatments, whether they be acute, or preemptive and prophylactic, to address treatable haemorrhological and haemodynamic abnormalities.

J Neurol Neurosurg Psychiatry 2002; 72: 564

REFERENCES

Author’s affiliations
M J Kushner, Eastern Carolina University School of Medicine and the Wilson Neurology Center, Wilson, North Carolina, USA

EDITORIAL COMMENTARIES

White matter change and stroke risk

P M Matthews

Large cohort studies have defined an increasing range of therapeutic interventions that can be applied to reduce stroke risk. However, application of these in a specialist practice is complicated by the problem of interindividual variation. A major practical issue is to differentiate those patients who will do well on standard treatment from those for whom a specifically targeted, more aggressive approach is needed. Ideally, it would be possible to profile patients at presentation to identify those at highest risk. If such a strategy could be made reliable, it would help simultaneously to balance a commitment to provide the best care available for each patient and to reassure government and other funders that potentially expensive therapeutic interventions are being employed in the most cost-effective fashion.

MRI provides an attractive tool for stratifying risk in a stroke population. It offers a good definition of brain injury and promises to deliver increasingly quantitative markers of specific pathological changes. With growing access to MRI scanners and routine imaging of stroke cases, even this relatively expensive “screening test” would be of potential

www.jnnp.com
value as a marker of risk if it can be shown to be both sensitive and prognostically useful. A fundamental problem that has thus far limited enthusiasm for the use of MRI in establishing prognosis (as opposed to establishing clinical-pathological correlations) has been the non-specificity of T2 hyperintensity—the most sensitive marker—on conventional MRI. T2 hyperintensity in white matter, for example, can arise from enlarged perivascular spaces, increased tissue fluid, inflammation, or gliosis. In the paper by Yamauchi et al (this issue pp576–82) there are important new observations suggesting that conventional T2 weighted MRI may provide clinically useful information for risk stratification in an older stroke population. This paper follows a series of communications from several groups showing correlations between recognised risk factors such as hypertension and clinical syndromes such as cognitive impairment.

Yamauchi et al followed prospectively 89 patients who either had symptomatic lacunar infarcts or who were neurologically normal and presented for other reasons. Subjects with large vessel disease were specifically excluded. White matter lesions were graded using a simple scoring system based on the extent and distribution of changes. Clinical monitoring and serial MRI studies were performed over a period of around four years to test the predictive value of white matter lesion changes at baseline and over time.

Seven patients had ischaemic or haemorrhagic strokes. These occurred only in patients with white matter lesions at baseline, and the proportion of patients who had stroke was greater in those with more severe white matter lesion changes than in those with milder white matter lesions. A Cox proportional hazards model identified both the expected risk factors for stroke (hypertension, uncontrolled diabetes mellitus, and smoking) and also the extent of white matter lesion changes. However, in a multiparametric model, the only independent predictors of stroke were the extent of the white matter lesions and uncontrolled diabetes mellitus. When patients with lacunar infarcts were considered separately, only the extent of white matter lesion changes was an independent predictor of later stroke.

Over the follow up period none of the patients showed regression of white matter lesions, suggesting irreversible pathology. Extending the association of white matter lesion extent with stroke risk found in the cross sectional studies, patients showing increases in white matter lesion load during the period of observation had a greater risk of later stroke.

The risk of stroke increases substantially after an initial cerebrovascular event. However, it has been less clear whether white matter changes can be interpreted as “silent strokes” that similarly contribute to risk. This study persuasively supports the notion that the extent of white matter lesion changes is an independent predictor and may provide prognostic information. Further work is needed to confirm these findings. Potential areas for such further work include the application of objective criteria for evaluation, the use of whole brain imaging, and thinner slices to improve the definition of changes. Nonetheless, Yamauchi et al offer the gratifying prospect of better targeting of aggressive management, although clearly a substantial therapeutic challenge remains—a disappointing observation in their study was that the severe white matter lesion group continued to have a higher risk of stroke despite apparently appropriate conventional management of vascular factors during the follow up period. Greater future effort might be directed towards developing therapeutic strategies directed at high risk populations, defined jointly by clinical and imaging measures.

J Neurol Neurosurg Psychiatry 2002;72:564–565

Author’s affiliations
P M Matthews, Centre for Functional MRI of the Brain, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK; paul@fmrib.ox.ac.uk

REFERENCES

Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer’s disease

C Ballard, J O’Brien, M Tovee

New approach to assessment of patients with dementia with Lewy bodies is clinically useful in differentiating them from patients with Alzheimer’s disease

A ccurate and early clinical diagnosis of dementia with Lewy bodies (DLB) is essential for optimal management so that pitfalls such as severe neuroleptic sensitivity can be avoided, a trial of cholinesterase treatment can be instigated, and parkinsonian symptoms can be appropriately treated, weighing up the balance of psychiatric and motor symptoms and fall risk. In practice it has often been difficult to differentiate DLB from other forms of dementia, particularly Alzheimer’s disease. Several previous studies have suggested that DLB and Alzheimer’s disease can be differentiated on the basis of visual and visuospatial tasks. The tasks most easily applicable to initial diagnosis are drawing tests (such as the clock drawing). However, this approach ignores what is one of the more striking features of DLB: fluctuating cognition. Operationalised criteria for the clinical diagnosis of DLB (which do consider a broad range of symptoms) have achieved high levels of specificity (> 90%); in many studies sensitivity has been as low as 50%. Probably the major obstacle to accurate diagnosis has been the difficulty of identifying fluctuating cognition; for example, two inter-rater reliability studies have indicated that agreement...
between expert clinicians is barely better than chance. A body of work focusing on these issues has validated two clinical rating scales and indicated that fluctuation of reaction time on attentional tasks and variability in spectral frequency assessed by electroencephalography can also be useful methods for identifying and quantifying fluctuating cognition, which seems to be closely linked to impairments of consciousness.

In the paper by Doubleday et al (this issue, pp 602–607) this issue, pp 602–607) tackles these issues in an innovative way. The authors developed a standardised qualitative instrument based on observations of the patient during the course of the testing session. Information is obtained regarding a number of helpful domains including general inattention, distraction, and intrusions. Of particular interest, general inattention, distractibility, and environmentally cued intrusions were all significantly more common in DLB than in Alzheimer’s disease, the latter occurring only in patients with DLB. In addition to the potential diagnostic value, this may be helpful in facilitating an understanding of the types of processing errors that are prominent in these patients. Perseveration and mental set shifting were also significantly more impaired in patients with DLB and they were more likely to confabulate.

This assessment method has been used as part of the standard diagnostic protocol that has achieved a high level of accuracy in 200 people with dementia at postmortem examination, although it is unclear how many of these people had neuropathologically confirmed DLB. Further work is needed to examine the inter-rater reliability and concurrent validity of the instrument, and comparisons between DLB and other dementias would also be helpful. In particular, patients with vascular dementia often experience some degree of fluctuating cognition and may be more prone to difficulties with set shifting and perseveration. Diagnostic discrimination between DLB and vascular dementia can be difficult and it would be useful to know whether the proposed assessment method can also contribute to this diagnostic issue. Therefore, although the method needs to be developed a little more, the work presents a new and useful approach that is very clinically applicable and that may be of considerable value in the assessment of patients with DLB.

J Neurol Neurosurg Psychiatry 2002;72:565–566

Authors’ affiliations
C Ballard, J O’Brien, M Tovee, Institute for Ageing and Health, Wolfson Research Centre, Newcastle upon Tyne, UK
Correspondence to: Professor C Ballard, Wolfson Research Centre, Institute for Ageing and Health, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK; c.g.ballard@newcastle.ac.uk

REFERENCES
White matter change and stroke risk

P M Matthews

*J Neurol Neurosurg Psychiatry* 2002 72: 564-565
doi: 10.1136/jnnp.72.5.564-a

Updated information and services can be found at:
http://jnnp.bmj.com/content/72/5/564.2

These include:

**References**
This article cites 4 articles, 1 of which you can access for free at:
http://jnnp.bmj.com/content/72/5/564.2#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Stroke (1449)
- Hypertension (380)
- Immunology (including allergy) (1943)
- Injury (478)
- Memory disorders (psychiatry) (1390)
- Neurological injury (390)
- Trauma (479)
- Trauma CNS / PNS (390)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/